CD Biosynsis offers specialized Nannochloropsis spp. Strain Development and Screening Services, providing a high-throughput, integrated pipeline to create, isolate, and validate superior algal variants for industrial applications. As one of the most promising oleaginous microalgae for the production of biofuels, omega-3 fatty acids (EPA), and high-value pigments, Nannochloropsis species require precise genetic tuning and rigorous selection to perform reliably in large-scale systems. Our services combine advanced genome editing with automated screening platforms to identify strains with optimized growth kinetics, enhanced metabolic flux, and verified genetic stability.
Developing an industrial-ready Nannochloropsis strain involves navigating its robust cell wall and complex metabolic regulation. Our comprehensive program utilizes a data-driven approach, moving beyond traditional random mutagenesis toward rational strain design. We provide end-to-end support, from the initial computational mapping of metabolic pathways to the final characterization of lead clones in simulated production environments. Whether you are targeting carbon sequestration or high-titer lipid production, our platform ensures that your Nannochloropsis strains are genetically defined, monoclonal, and fully optimized for performance in photobioreactors or open ponds.
Get a QuoteNannochloropsis strain development requires a systematic "Design-Build-Test-Learn" cycle that accounts for the haploid nature of the genome and its efficient yet tightly regulated carbon partitioning mechanisms. Our platform focuses on identifying "High Lipid Mutants" (HLMs) and robust growth variants by processing thousands of monoclonal candidates simultaneously. We employ automated screening systems to evaluate photosynthetic efficiency and lipid productivity under varied environmental stresses, ensuring that only the most resilient and productive strains advance to the scale-up phase.
Our analytical team integrates transcriptomic and lipidomic profiling to characterize lead candidates. By understanding the mechanistic basis for improved performance—such as the downregulation of starch synthesis or the upregulation of specific fatty acid desaturases—we can iteratively refine our engineering strategies. This holistic approach ensures that the final delivered strain is not only a high producer but also maintains its metabolic traits over dozens of generations, minimizing the risk of phenotypic reversion during commercial-scale biomanufacturing.
We provide a diversified toolkit of technologies to construct and screen high-performance Nannochloropsis strains tailored to your specific bioproduct goals.
Targeted Editing
Utilizing CRISPR-Cas9/Cas12a for precise knockouts and knock-ins to create specific metabolic phenotypes, such as redirecting carbon from carbohydrate to lipid pathways.
Inducible Systems
Implementing inducible promoters to trigger lipid accumulation or protein expression at the optimal growth phase, maximizing biomass before production.
FACS-Based Sorting
High-speed, single-cell isolation using fluorescence-activated cell sorting (FACS) to identify clones with high neutral lipid content via Nile Red staining.
PAM Fluorometry
Microplate-based screening of photosynthetic health (Fv/Fm) to identify strains that maintain high light-harvesting efficiency under industrial stressors.
Lipidomics Profiling
Quantitative analysis using GC-MS and HPLC to verify the specific fatty acid profile (e.g., EPA/TAG ratios) and pigment titers of lead candidates.
Passage Stability
Verification of genotype and phenotype stability over 30 to 50 generations to ensure the strain is ready for industrial scale-up.
Our systematic technical pipeline ensures high-precision engineering and data-driven selection of industrial lead strains.
1. Computational Design
2. Genetic Engineering
3. High-Throughput Screening
4. Scale-up & Stability
Establishment of target strain profiles and metabolic flux analysis. Codon optimization and gRNA design for the Nannochloropsis nuclear and chloroplast genomes.
Transformation via optimized high-voltage electroporation or biolistics. Delivery of CRISPR machinery (RNPs or episomes) to create biallelic or haploid modifications.
Evaluation of lead clones in lab-scale photobioreactors under fluctuating light/CO2. Verification of long-term phenotypic stability. Delivery of Master Cell Banks and technical data.
Industrial Relevance
Screening protocols simulate real-world photobioreactor conditions, ensuring strains perform in the field, not just the lab.
Monoclonality Guaranteed
Rigorous single-cell isolation and genomic verification ensure every delivered strain is a pure, genetically defined clone.
Metabolic Depth
Lead strains are characterized with full lipidomic and omics profiling to confirm bioproduct titers and pathway performance.
Verified Stability
Extended stability trials over 50 passages ensure that engineered traits remain fixed and consistent across generations.
1. How do you ensure the genetic stability of the developed strains?
Stability is verified through continuous subculturing (at least 30-50 passages) followed by re-genotyping and phenotypic analysis to ensure no drift occurs.
2. Can you perform strain development on industrial Nannochloropsis isolates?
Yes, we can optimize transformation and screening protocols for proprietary industrial isolates beyond standard lab strains like N. oceanica W2J3B.
3. What is the advantage of FACS-based screening for lipids?
FACS allows for the ultra-fast screening of millions of individual cells, enabling the isolation of rare high-lipid mutants that would be missed by traditional methods.
4. Do you offer strains optimized for both biofuels and omega-3 production?
Yes, we have specialized metabolic strategies to target either total TAG accumulation for fuels or specific EPA enrichment for nutraceuticals.
5. How is the "metabolic burden" managed during strain design?
We utilize Flux Balance Analysis (FBA) to predict the metabolic impact of genetic edits, ensuring that growth rates are maintained alongside high productivity.
6. Is the screening performed under specific CO2 conditions?
We can screen strains under high CO2 levels (e.g., flue gas concentrations) to identify clones optimized for carbon capture and utilization.
7. What type of documentation is included with the final strain?
A comprehensive technical report is provided, including genomic sequencing, growth curves, lipid profiles, and photosynthetic data.
8. What is the typical lead time for a custom strain development project?
Depending on the modifications and screening parameters, projects typically range from 18 to 24 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.